Lipid-based Nanoparticles for Nucleic Acid Delivery

Purpose: Systemic non-viral gene delivery is limited by rapid clearance, toxicity, and poor target-cell access. Cationic lipid–DNA lipoplexes are effective in vitro but perform poorly in vivo because they aggregate with serum proteins, are cleared by the reticuloendothelial system (RES), and accumulate mainly in lung and liver rather than target tissues. There is a need for stable, sub-100 nm lipid nanoparticles that encapsulate nucleic acids, circulate longer, and deliver cargo more effectively.

Hypothesis: If nucleic acids are encapsulated into small (<100 nm), PEG-shielded, charge-neutral or anionic lipid nanoparticles using controlled assembly methods, then the particles can avoid rapid serum protein binding and RES clearance, extravasate at disease sites, and improve systemic delivery of DNA, siRNA, or oligonucleotides.

Aims: Distinguish lipid nanoparticles (NP) from conventional cationic lipoplexes. - Review barriers to systemic nucleic acid delivery: blood components, RES uptake, tumor access, extracellular matrix, and intracellular trafficking. - Summarize formulation factors affecting NP diameter and encapsulation efficiency. - Describe components: cationic lipids, neutral/helper lipids, anionic lipids, PEG-lipids, targeting ligands, and lipid–polymer conjugates. - Review assembly methods: direct mixing, detergent dialysis, ethanol dialysis, template-directed assembly, and molded fabrication. - Highlight in vivo performance and prospects, especially for siRNA versus plasmid DNA.

Delivery system: Platform: lipid-based nanoparticles (NP), typically <100 nm, with an encapsulated nucleic acid core and a lipid bilayer shell; distinct from unordered cationic lipoplexes. - Payloads: plasmid DNA, siRNA, antisense oligonucleotides (ODN). - Key components: - Cationic lipids for nucleic acid condensation. - Neutral/helper lipids such as DOPE and cholesterol. - Anionic lipids for charge-neutral or anionic surface coatings. - PEG-lipids for steric shielding and prolonged circulation. - Targeting ligands: RGD peptides, folate, antibodies, transferrin. - Lipid–polymer conjugates such as cholesterol-modified PEI. - Formulation methods: direct mixing; detergent dialysis; ethanol dialysis; organic solvent methods; template-directed assembly; PRINT molded fabrication. - Design goal: small size, neutral surface, stability in blood, and triggered release inside target cells.

Approach: Review and synthesis of in vitro, in vivo, and formulation literature. Cited models include mice, rats, non-human primates, tumor models, brain tumor models, and cell culture systems such as MDA-MB-231. The review compares lipoplexes, stabilized plasmid–lipid particles (SPLP), nanolipoparticles (NLP), stable nucleic acid–lipid particles (SNALP), and related systems. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - Particle size and zeta potential measurements. - DNase protection assays for nucleic acid encapsulation. - Anion-exchange chromatography for purification. - In vivo circulation half-life and biodistribution. - Gene expression and RNAi silencing assays. - Tumor accumulation via the enhanced permeability and retention (EPR) effect. - Safety/immunogenicity assessments after single and repeat dosing.

Key results: Lipoplexes have a blood half-life of <5 min; less than 2% remain in circulation 10 min after injection, and most redistribute from lung to liver within 60 min. - PEG-shielded lipid NPs typically have circulation half-lives of 1–10 h; SPLP half-life is 5–15 h in mice. - Standard detergent dialysis gave DNA encapsulation of 40–50%; low-detergent (28 mM OG) NLP dialysis improved encapsulation to 80–100% with 75% less total lipid. - NLP diameters were about 80–150 nm; SNALP/ethanol-dialysis particles were 100–150 nm with 80–90% DNA encapsulation. - ApoB-specific siRNA delivered by SNALP in monkeys produced dose-dependent reduction of ApoB mRNA in liver at 48 h and significant lowering of serum cholesterol and LDL as early as 24 h, persisting for 11 days. - Repeated administration of PEGylated SNALP can induce anti-PEG antibodies, reducing efficacy and increasing adverse events; chemical modification of siRNA or dexamethasone predosing can reduce immunostimulation. - siRNA is easier to deliver than plasmid DNA: releasing a 20-mer siRNA requires breaking about 40 ionic interactions, whereas releasing a 4,000 bp plasmid requires disrupting roughly 8,000 ionic pairs; siRNA also acts in the cytosol, avoiding the nuclear barrier.

Interpretation: The authors conclude that PEG-shielded, sub-100 nm lipid nanoparticles are a robust but only modestly effective system for systemic gene or siRNA delivery. They argue that siRNA delivery will likely progress faster than plasmid DNA delivery because of its smaller size, cytosolic target, and easier release from cationic lipids. Improved multi-component assembly, better ligands, and scalable manufacturing are needed to make NP a truly efficient systemic nucleic acid delivery platform.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - NP are not yet an efficient delivery vector for plasmid DNA. - Multi-component particles often do not work synergistically; assembly is difficult to control. - Cationic lipids cause toxicity, inflammation, complement activation, and RES uptake. - PEGylation improves circulation but can reduce cell uptake and induce anti-PEG immune responses after repeated dosing. - Extracellular matrix, endosomal escape, and nuclear delivery remain major barriers for DNA. - Scale-up, storage stability, and robust analytical characterization are still needed for clinical translation.